UBS Trims TIGERMED (03347.HK) TP to $173.82, Rated Buy
UBS Trims TIGERMED (03347.HK) TP to $173.82, Rated Buy
TIGERMED (03347.HK) will likely benefit from the more stringent new regulations on anti-tumor drugs introduced by China National Medical Products Administration (NMPA), while its overseas business is believed to be able to serve as a new growth driver, reported UBS. The broker kept the Buy rating for TIGERMED, while cutting its target price from $246.76 to $173.82.
UBS added that the strong order backlog of TIGERMED will ensure the earnings growth of the company in short to medium term.
The company has more than 140 overseas clinical trial projects and over 30 global multi-center clinical trials. With more Chinese innovative drug R&D companies poised to venture into the overseas market, the overseas operation of TIGERMED is expected to enjoy ample room of growth, the broker remarked.
据瑞银报道，泰格医药(03347.HK)可能会受益于中国国家医药品监督管理局(NMPA)出台的更严格的抗肿瘤药物新规，而其海外业务被认为能够成为新的增长动力。该经纪商维持对泰格医药的买入评级，同时将其目标价从246.76美元下调至173.82美元。
瑞银补充称，泰格医药的强劲积压订单将确保公司中短期的盈利增长。
该公司拥有140多个海外临床试验项目和30多个全球多中心临床试验。这位经纪人表示，随着更多的中国创新药物研发公司准备进军海外市场，泰格医药的海外业务预计将有很大的增长空间。
